Dramatic Twists Could Upend, But Investors Shy Away: Editas Medicine, Inc. (EDIT), VIVUS, Inc. (VVUS)

Editas Medicine, Inc. (NASDAQ:EDIT) recent rally took place on significantly less volume which dipped to nearly 0.79 million contracts on 21-Nov-17 versus its daily average of 1.09 million. The first sale was made at $25.63 but later the stock became weaker, and closed with a gain of 1.92%. It was last traded at $25.95 apiece.

Editas Medicine, Inc. (EDIT): Outperform Candidate With 27.98% Upside Potential

Editas Medicine, Inc. is maintained at an average outperform rating by 8 stock analysts, and there are at least 19.41% of shares outstanding that are currently legally short sold. The shares went up by 8.71% in value last month. Year-to-date it jumped 59.89%. Analysts are turning out to be more optimistic than before, with 4 of analysts who cover Editas Medicine, Inc. (NASDAQ:EDIT) advice adding it to buy candidate list. Wall Street experts also assign a $33.21 price target on Editas Medicine, Inc., pointing towards a 27.98% rally from current levels. The stock is trading for about -11.13% less than its 52-week high.

Editas Medicine, Inc. Reports 1.61% Sales Growth

Editas Medicine, Inc. (EDIT) remained unsuccessful in beating the consensus-estimated -$0.6 as it actually earned -$0.64 per share in its last reported financial results. Revenue, on the other hand, scored 1.61% growth from the previous quarter, coming up with $3.15 million.

EDIT Adds 10.19% In A Week

This company shares (EDIT) so far managed to recover 97.79% since collapsing to its 52-week low. Over a month, it has seen its stock price volatility to stay at 5.04% while shortening the period to a week, volatility was 6.7%. The share price has already crossed its 20 days moving average, floating at a distance of 9.2% and sits 11.26% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 10.19% gains and is up by 28.24% compared with its 200-day moving average of $19.68. Also, Editas Medicine, Inc. (EDIT) needs to expand a 65.71% increase it experienced over the past twelve months.

VIVUS, Inc. (NASDAQ:VVUS) Consensus Call At 3

As regular trading ended, VIVUS, Inc. (VVUS) stock brought in a -$0.01 drop to $0.66. The day started at a price of $0.671 but then traded as high as $0.6818 before giving part of the gains back. As for this week, analysts appear content to stick with their bleak outlook with the consensus call at 3. VIVUS, Inc. is given 0 buy-equivalent recommendations, 0 sells and 1 holds. The company shares sank -54.9% from their peak of $1.47 and now has a $70.84 million market value of equity.

VIVUS, Inc. Could Grow 127.27% More

VVUS’s mean recommendation on Reuter’s scale presents no change from 3 thirty days ago to 3 now, which indicates a hold consensus from the analyst community. They see VIVUS, Inc. (VVUS) price hitting a mean target of $1.5 a share, meaning the stock still has potential that could lift the price another 127.27% Also, the recent close suggests the stock is underpriced by 127.27% compared to the most bullish target.

VIVUS, Inc. (VVUS) Returns -42.35% This Year

The company had seen its current volume reaching at 0.38 million shares in the last trade. That compares with the recent volume average of 0.82 million. At the close of regular trading, its last week’s stock price volatility was 6.67% which for the month reaches 5.12%. VIVUS, Inc. dipped to as low as $0.6611 throughout the day and has returned -42.35% in this year. At one point in the past year, the shares traded as low as $0.61 but has recovered 8.69% since then.

Previous articleWhat Really Matters? – Ampio Pharmaceuticals, Inc. (AMPE), ZIOPHARM Oncology, Inc. (ZIOP)?
Next articleWhat’s In Store For Sarepta Therapeutics, Inc. (SRPT), Conatus Pharmaceuticals Inc. (CNAT)?